Connect with us

Uncategorized scores $20M for a supportive approach to customer service automation


on, a virtual customer service agent builder, has closed a $20 million Series A round of funding, led by Omers Ventures with participation from Felicis Ventures and existing investors HV Capital, and — bringing its total raised to date to $25M+.

The European startup’s flagship claim for the data-ingesting bot-builder platform is it’s capable of automating up to 80% of customer support interactions.

The focus, as tends to be the case for all these customer service conversational AI plays, is freeing (human) support agents from dealing with dull, repetitive stuff — so they can apply their (less limited) skills to more complex, consultative or emotionally demanding customer queries.

When we last spoke to the Helsinki- and Berlin-based startup, back in 2018 for a $1.3M seed round, it described itself as a “language-agnostic” conversational AI — having started out with the hard (linguistic) challenge of Finnish — claiming that gave it an edge in a competitive space with customers in non-English speaking markets. (Though it did also tackle English too.)

Two years on the startup’s marketing focus is broader; today it talks about its customer service automation platform as an “AI-first” ‘no code’ tool — sating it wants to empower b2c users to get the most out of AI by helping them design virtual agents that can usefully handle complex customer interactions. will hand-hold you through the process of building a super savvy customer service robot, is the pitch.

Co-founder and CEO Reetu Kainulainen claims it’s always been “no code and intuitive” — though there’s now a handy reference label to align what it’s doing with a wider b2b trend. (‘No code’ or ‘low code’ referring to a digital tool-building movement that aims to widen access to powerful technologies like AI without the need for the user to possess deep technical know-how in order to make useful use of them.)


“Everything we build is to guide users to creating the best virtual agents. The whole user journey — discovery, design, expansion — is all within,” Kainulainen tells TechCrunch.

“In the past two years, we have been laser focused on building a very deep customer service automation platform — one that goes beyond simple FAQ answers in chat — and enables brands to design complex, personalized workflows that can be deployed across all digital support channels.

“We believe that customer service automation will be its own category in the future and so we are working hard to define what that means today.”

As an example, Kainulainen points to “one click” integration with “any major CRM” (including Salesforce and Zendesk) — which lets customers quickly import existing customer support logs so’s platform can analyze the data to help them build a useful bot.

“Immediately, you are shown a breakdown of your most common customer service cases and the impact automation can have for your business,” he goes on, saying the platform shows templates and “best practices” to help the customer design their automation workflows — “tailored for your cases and industry”.

Once a virtual agent is live users can run A/B tests via the platform to check and optimize performance — and, here too, the promise is further hand-holding, with Kainulainen saying it will “proactively suggests new cases and data to improve your virtual agent”.

“Where we are very strong is in large-scale customer support organizations, who are looking for a holistic, advanced automation platform that can be managed and implemented by non-technical users,” he says.

“The bigger picture is that each of our competitors views the opportunity more narrowly than does: Our best competitors are either focused on chatbots only, or otherwise limited to the ecosystem of their mother company. Our vision has always been the big picture: Of automation becoming one of the primary means of providing customer service.”

Having multilingual smarts remains an advantage, with’s virtual agents able to handle interactions in over 20 languages at this point.

“Our market — the customer service automation market — has a lot of players,” Kainulainen goes on, name-checking the likes of Ada Support and Einstein Bots (Salesforce’s own solution) as key competitors.

“This is because it is new and, until recently, solutions were so early that there were virtually no barriers to entry. But the market has changed a lot in the last four years. There are now only a handful of players globally that are worth paying attention to and we are one of them.”

The 2016-founded startup is hitting the nail on the head for a growing number of customers — with close to 100 signed up to its platform at this point, including the likes of Deezer, Telia, Footasylum, and Finnair. Per Kainulainen, it works best for “b2c brands with large (and often repetitive) customer service volumes”.

“This is where automation can provide a huge impact from day one and really free up people to take on more creative and challenging work. We have a broad customer base of close to 100 great brands… and do particularly well in industries like retail/ecommerce, telecommunications and travel,” he adds.

It’s enjoyed a major growth spurt this year, as businesses of all stripes were forced to ramp up their attention to online customer interactions as the coronavirus pandemic became an engine for digital activity.

Customer retention has also risen in priority for many businesses, as a highly contagious virus and public health safety measures put in place to reduce its spread, flipped markets into recession — which Kainulainen points to as another growth driver.

Overall, he says it’s tripled ARR over the last 12 months (albeit, it was the same growth story last year too). Plus it’s tripled headcount to deal with the COVID-19 effect.

Now is gearing up for fresh growth — saying it’s expecting major developments next year.

“COVID-19 has… prompted one of the most accelerated periods of change in the customer service industry,” says Kainulainen, predicting 2021 will bring “immense innovation” in the space — and that “booming” automation technologies will take “center stage”.

Of course it’s a convenient narrative for a customer service chatbot maker to tell.

But COVID-19 is clearly accelerating digital transformation of consumer focused businesses — a movement that, logically, pumps demand for smarter tools to handle online customer support. So those positioned to harness new momentum for customer service automation — by being able to offer an accessible, scalable and effective product (as claims it does) — are sitting pretty in the middle of a pandemic.

“We believe that the best product will win this market,” adds Kainulainen. “We have a big vision for what we want to be. Market maturity for our technology has accelerated massively in 2020, achieving in one year what could have probably taken five. We will capitalize on that by building more, faster.”

The Series A funding will go on sales and marketing, with a planned market push in North America and a desire to go deeper throughout Europe, as well as being ploughed into further product development.

And while — clearly — not every potential b2c customer will be able to ‘automagic’ away 80% of their customer support pings, Kainulainen argues can still offer a compelling sales pitch to businesses with more “consultative” customer support needs, where automation will only be able to play a far more limited role.

“There’s often a strong correlation between how consultative a customer service organization needs to be and how highly trained and experienced their team is. In other words, it is often the case that organizations with ‘lower bound’ automation potential also only need 10% automation to still drive a huge ROI,” he suggests.

“For example, one of our customers is a large national pharmacy group, where customer service agents are qualified pharmacists who provide prescription medical advice. Here, the goal isn’t to achieve a very high automation rate but rather to automate basic, repetitive processes to free up the pharmacists for more challenging tasks that better use their capabilities.

“For this customer, in addition to the automation of simple requests (which alone provides a huge value) our real-time answer recommendations help pharmacists respond faster and easier.”

Commenting on the Series A in a statement, Omers Ventures managing partner, Jambu Palaniappan, dubbed the startup’s growth “truly spectacular”, as well as lauding its “world-class team” and founders “with a strong vision and unrivalled knowledge of AI”.

“There are numerous chatbot companies out there but represents something much bigger because at its core is an automation company with massive potential,” he added. “We look forward to working with Sarah, Reetu, Jaakko, and Markus as they expand internationally and advance their deep product capabilities even further.”

“The customer service industry is undergoing an automation revolution. In, we saw a vision that’s bold enough to lead the way,” added Aydin Senkut, founder and managing partner of Felicis Ventures, in another supporting statement. “We believe that, just in the same way that category leaders have defined marketing and sales automation, will do the same for customer service.”

Jambu Palaniappan, managing partner at Omers Ventures, will join the board. Aydin Senkut, founder and managing partner of Felicis Ventures, will join as an investor, alongside former head of Airbnb for Business Mark McCabe, and former EVP global sales of payment giant Adyen, Thijn Lamers.

Lyron Foster is a Hawaii based African American Musician, Author, Actor, Blogger, Filmmaker, Philanthropist and Multinational Serial Tech Entrepreneur.

Continue Reading


The one-shot vaccine from Johnson & Johnson now has FDA support in the US



An advisory board to the US Food and Drug Administration voted unanimously in favor of the first single-shot covid-19 vaccine, clearing the path for the health agency to authorize its immediate use as soon as tomorrow.

The one-shot vaccine, developed by Johnson & Johnson, has the additional advantage of being easy to store, because it requires nothing colder than ordinary refrigerator temperatures. It stopped 66% of mild and serious covid-19 cases in a trial carried out on three continents.

It will join a US covid arsenal that already includes authorized vaccines from Moderna and Pfizer. Those vaccines, which use messenger RNA, were significantly more effective (they stopped about 95% of cases), but they require two shots, and the doses need to be stored at ultra-cold temperatures.

Globally, a growing list of injections developed in Russia, China, India, and the United Kingdom all are starting to see wide use.

While the new J&J vaccine isn’t as effective as those made using messenger RNA technology, health officials said that shouldn’t dissuade people from getting it, since it still sharply reduces the chance of illness and death.

“To have two is fine, and having three is absolutely better,” Anthony Fauci, the country’s chief virologist, said during an interview on NBC. “It’s more choices and increases the supply. It will certainly contribute to getting control.”

In the US, there have been approximately 28 million confirmed cases of covid-19 and 500,000 deaths.

The limited supplies of the Moderna and Pfizer shots mean most Americans are still waiting to be vaccinated. About 1.4 million doses of those two vaccines were given each day last week in the US. At that pace it would take about a year to vaccinate the whole nation.

In theory, an easily stored single-shot vaccine could kick up the pace. In practice, though, supply shortages of the J&J vaccine could limit the role it plays in the US vaccination campaign. In testimony before Congress this week, Johnson & Johnson said it had only 4 million shots ready to go, a third of the initial supply promised, and would deliver only 20 million doses by the end of March.

“I wonder if the J&J vaccine is going to be a significant part of the US landscape,” says Eric Topol, a doctor at the Scripps Research Institute, who called initial supplies “paltry” given that the company received extensive government support.

The vaccine also has what Topol called a “notable dropdown in efficacy overall” compared with messenger RNA shots, although many health experts this week rushed to defend the vaccine against any suggestion it was inferior.

“Everything we’ve seen so far says these are excellent vaccines,” Ashish Jha, a health policy researcher and doctor at Brown University, wrote on Twitter, where he argued that comparing “headline efficacy” among vaccines can be misleading since “they all are essentially 100% at preventing hospitalizations [and] deaths once they’ve kicked in.”

New shot

The new one-shot vaccine, called Ad26.COV2.S, was developed by Johnson & Johnson using work from Beth Israel Deaconess Medical Center in Boston. It employs a harmless viral carrier, adenovirus 26, which can enter cells but doesn’t multiply or grow. Instead, the carrier is used to drop off gene instructions that tell a person’s cells to make the distinctive coronavirus spike protein, which in turn trains the immune system to combat the pathogen.

The New York Times published a detailed graphical explanation of how the vaccine works.

Richard Nettles, vice president of US medical affairs at Janssen, a J&J subsidiary, told Congress during testimony on February 23 that production of the vaccine is “highly complex” and said the company was working to manufacture the shots at eight locations, including a US site in Maryland.

The manufacturing is complicated because the vaccine virus is grown in living cells before it is purified and bottled. Making a batch of virus takes two months, which is why there is no way to immediately increase supplies if timelines are missed.

Indeed, the biggest disappointment around the new vaccine is a supply shortfall caused by manufacturing problems. Jeffrey Zients, coordinator of President Biden’s covid-19 task force, said during a White House press conference on Wednesday, February 24, that the new administration had only “learned that J&J was behind on manufacturing” when it took office five week ago.

“It was disappointing when we arrived,” he said. “The initial production ramp … was slower than we’d like.”

Pretty effective

In late January, the company announced results from a 45,000-person study it carried out in the US, South Africa, and South America, in which people got either the vaccine or a placebo.

Overall, the vaccine was 66% effective in stopping covid-19, and somewhat better at stopping severe disease. In the trial, for instance, seven people died of covid-19, but all of these were in the placebo arm. Also, its effects increased with time—after a month, no one in the vaccine arm had to go to the hospital for covid-19.

Johnson & Johnson claims it will not be making a profit from the vaccine, which will also be sold outside the US. Instead, Nettles said, the vaccine will be sold at a single “not-for-profit” price to all countries “for emergency pandemic use.”

Nettles didn’t say what that price would be, but the US agreed last year to pay the company about $1 billion for a guarantee of 100 million doses and has given the company a similar amount of development funding, making it one of the major investments of Operation Warp Speed, as the vaccine effort was known during the Trump administration.

Shortage to surplus

At least for the moment, vaccine supply remains a limiting factor in the US inoculation campaign, which has seen 70 million doses administered since it began in December, according to Bloomberg. “I don’t see an excess of vaccine for a while,” says Peter Hotez, a virologist and vaccine developer at the Baylor College of Medicine.

All told, the US will have received enough shots to fully vaccinate 130 million Americans by the end of March, when projected supplies from Pfizer, Moderna, and J&J are tallied together.

Still, vaccine shortages could turn to excess before summer, creating a situation in which it’s no longer vaccines that are in short supply, but people willing or eligible to receive them.

That is because in the US, children under 18 make up about a quarter of the population but aren’t yet allowed to receive the shots. As well, about 30% of American adults claim they won’t get a covid-19 vaccine at all. Children and vaccine doubters together make up half the population.

By August, the three companies say, they will deliver the US enough vaccines for 400 million people, or more than the country’s population. That does not account for a fourth vaccine, manufactured by Novavax, that may also win US authorization.

“By the summer we will be in good shape. The question is how we navigate this space between now and June,” says Hotez.

Growing arsenal

The Johnson & Johnson shot joins a growing worldwide list of approved vaccines that includes the two messenger RNA vaccines, injections from AstraZeneca and Chinese manufacturers, and Russia’s “Sputnik” vaccine, all of which are in use outside the US.

People who get any of the vaccines will, on average, see their chance of dying from covid-19 plummet to near zero. That is down from an overall death rate of around 1.7% of diagnosed cases in the US—and a risk several times higher in elderly people.

The J&J shot has fewer side effects than the mRNA vaccines and has also proved effective against a highly transmissible South African variant of the virus that has accumulated numerous mutations.

The South Africa variant has alarmed researchers because it clearly decreases the effectiveness of some vaccines. A study in South Africa by AstraZeneca found its vaccine didn’t offer protection against the variant at all, causing officials to scrap a plan to distribute the shot there.

According to health minister Zweli Mkhize, South Africa is instead pivoting to the J&J vaccine, with a plan to vaccinate 80,000 health-care workers in the next two weeks.

This week, Moderna also said it would develop a shot tailored against the South African variant, and Pfizer indicated it was also preparing to counter new strains as they arise. Another strategy being contemplated to fend off variants is to give people extra booster doses of the current vaccines.

Some experts in the US continue to urge the government to adopt faster-paced vaccine schemes, like delaying second doses of the messenger RNA shots or using half doses, arguing that the more people who have “good enough” protection, the sooner the pandemic will end.

So far, though, it’s not clear what agency or official would be ready, or even legally authorized, to make that call.

“We are all scratching our heads about who could make that decision,” says Hotez. “And it all depends on how much urgency you feel. The big picture is if you know the numbers are going down, and feel they are going to stay down due to seasonality, then you have some breathing space. But if you are worried about variants, then you have a problem, and you want to vaccinate ahead of schedule.”

On NBC, Fauci said people shouldn’t wait for the best vaccine but take what’s offered. “Even one that may be somewhat less effective is still effective against severe disease, as we have seen with the J&J vaccine,” he said. “Get vaccinated when the vaccine is available to you.”

Continue Reading


Daily Crunch: Facebook launches rap app



Facebook unveils another experimental app, Atlassian acquires a data visualization startup and Newsela becomes a unicorn. This is your Daily Crunch for February 26, 2021.

The big story: Facebook launches rap app

The new BARS app was created by NPE Team (Facebook’s internal R&D group), allowing rappers to select from professionally created beats, and then create and share their own raps and videos. It includes autotune and will even suggest rhymes as you’re writing the lyrics.

This marks NPE Team’s second musical effort — the first was the music video app Collab. (It could also be seen as another attempt by Facebook to launch a TikTok competitor.) BARS is available in the iOS App Store in the U.S., with Facebook gradually admitting users off a waitlist.

The tech giants

Atlassian is acquiring Chartio to bring data visualization to the platform — Atlassian sees Chartio as a way to really take advantage of the data locked inside its products.

Yelp puts trust and safety in the spotlight — Yelp released its very first trust and safety report this week, with the goal of explaining the work that it does to crack down on fraudulent and otherwise inaccurate or unhelpful content.

Startups, funding and venture capital

Newsela, the replacement for textbooks, raises $100M and becomes a unicorn —  If Newsela is doing its job right, its third-party content can replace textbooks within a classroom altogether, while helping teachers provide fresh, personalized material.

Tim Hortons marks two years in China with Tencent investment — The Canadian coffee and doughnut giant has raised a new round of funding for its Chinese venture.

Sources: Lightspeed is close to hiring a new London-based partner to put down further roots in Europe — According to multiple sources, Paul Murphy is being hired away from Northzone.

Advice and analysis from Extra Crunch

In freemium marketing, product analytics are the difference between conversion and confusion — Considering that most freemium providers see fewer than 5% of free users move to paid plans, even a slight improvement in conversion can translate to significant revenue gains.

As BNPL startups raise, a look at Klarna, Affirm and Afterpay earnings — With buy-now-pay-later options, consumers turn a one-time purchase into a limited string of regular payments.

(Extra Crunch is our membership program, which helps founders and startup teams get ahead. You can sign up here.)

Everything else

Jamaica’s JamCOVID pulled offline after third security lapse exposed travelers’ data — JamCOVID was set up last year to help the government process travelers arriving on the island.

AT&T is turning DirecTV into a standalone company — AT&T says it will own 70% of the new company, while private equity firm TPG will own 30%.

How to ace the 1-hour, and ever-elusive, pitch presentation at TC Early Stage — Norwest’s Lisa Wu has a message for founders: Think like a VC during your pitch presentation.

The Daily Crunch is TechCrunch’s roundup of our biggest and most important stories. If you’d like to get this delivered to your inbox every day at around 3pm Pacific, you can subscribe here.

Continue Reading


Salesforce delivers, Wall Street doubts as stock falls 6.3% post-earnings



Wall Street investors can be fickle beasts. Take Salesforce as an example. The CRM giant announced a $5.82 billion quarter when it reported earnings yesterday. Revenue was up 20% year over year. The company also reported $21.25 billion in total revenue for the just closed FY2021, up 24% YoY. If that wasn’t enough, it raised its FY2022 guidance (its upcoming fiscal year) to over $25 billion. What’s not to like?

You want higher quarterly revenue, Salesforce gave you higher revenue. You want high growth and solid projected revenue — check and check. In fact, it’s hard to find anything to complain about in the report. The company is performing and growing at a rate that is remarkable for an organization of its size and maturity — and it is expected to continue to perform and grow.

How did Wall Street react to this stellar report? It punished the stock with the price down over 6%, a pretty dismal day considering the company brought home such a promising report card.

2/6/21 Salesforce stock report with stock down 6.31%

Image Credits: Google

So what is going on here? It could be that investors simply don’t believe the growth is sustainable or that the company overpaid when it bought Slack at the end of last year for over $27 billion. It could be it’s just people overreacting to a cooling market this week. But if investors are looking for a high growth company, Salesforce is delivering that

While Slack was expensive, it reported revenue over $250 million yesterday, pushing it over the $1 billion run rate with more than 100 customers paying over $1 million in ARR. Those numbers will eventually get added to Salesforce’s bottom line.

Canaccord Genuity analyst David Hynes Jr wrote that he was baffled by investor’s reaction to this report. Like me, he saw a lot of positives. Yet Wall Street decided to focus on the negative, and see “the glass half empty” as he put it in his note to investors.

“The stock is clearly in the show-me camp, which means it’s likely to take another couple of quarters for investors to buy into the idea that fundamentals are actually quite solid here, and that Slack was opportunistic (and yes, pricey), but not an attempt to mask suddenly deteriorating growth,” Hynes wrote.

During the call with analysts yesterday, Brad Zelnick from Credit Suisse asked how well the company could accelerate out of the pandemic-induced economic malaise, and Gavin Patterson, Salesforce’s president and chief revenue officers says the company is ready whenever the world moves past the pandemic.

“And let me reassure you, we are building the capability in terms of the sales force. You’d be delighted to hear that we’re investing significantly in terms of our direct sales force to take advantage of that demand. And I’m very confident we’ll be able to meet it. So I think you’re hearing today a message from us all that the business is strong, the pipeline is strong and we’ve got confidence going into the year,”Patterson said.

While Salesforce execs were clearly pumped up yesterday with good reason, there’s still doubt out in investor land that manifested itself in the stock starting down and staying down all day. It will be as Hynes suggested up to Salesforce to keep proving them wrong. As long as they keep producing quarters like the one they had this week, they should be just fine, regardless of what the naysayers on Wall Street may be thinking today.

Continue Reading